| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Anticonvulsants | 2 | 2018 | 634 | 0.93 | Why? |
| Meningitis, Fungal | 1 | 2021 | 17 | 0.93 | Why? |
| Hantaan virus | 1 | 2020 | 5 | 0.89 | Why? |
| Antiviral Agents | 12 | 2021 | 41703 | 0.88 | Why? |
| Hydroxybutyrates | 1 | 2021 | 162 | 0.86 | Why? |
| Hemorrhagic Fever with Renal Syndrome | 1 | 2020 | 31 | 0.85 | Why? |
| Crotonates | 1 | 2021 | 141 | 0.85 | Why? |
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2021 | 106 | 0.85 | Why? |
| Toluidines | 1 | 2021 | 145 | 0.84 | Why? |
| Medicine, Ayurvedic | 1 | 2021 | 155 | 0.78 | Why? |
| Folic Acid | 1 | 2021 | 172 | 0.78 | Why? |
| Nose Diseases | 1 | 2021 | 139 | 0.78 | Why? |
| Cefixime | 1 | 2018 | 6 | 0.76 | Why? |
| Trichomonas vaginalis | 1 | 2018 | 19 | 0.76 | Why? |
| Drug Evaluation, Preclinical | 3 | 2020 | 3347 | 0.75 | Why? |
| Giardia lamblia | 1 | 2018 | 20 | 0.75 | Why? |
| Honey | 1 | 2018 | 21 | 0.74 | Why? |
| Endocannabinoids | 1 | 2018 | 56 | 0.72 | Why? |
| Hydroxychloroquine | 6 | 2021 | 12447 | 0.71 | Why? |
| Antiprotozoal Agents | 1 | 2018 | 83 | 0.71 | Why? |
| Neuroprotective Agents | 2 | 2019 | 240 | 0.70 | Why? |
| Investigational New Drug Application | 1 | 2017 | 75 | 0.70 | Why? |
| Placebos | 1 | 2021 | 629 | 0.70 | Why? |
| Medical Marijuana | 1 | 2018 | 55 | 0.68 | Why? |
| Consumer Product Safety | 1 | 2017 | 57 | 0.68 | Why? |
| Orphan Drug Production | 1 | 2017 | 31 | 0.67 | Why? |
| Plant Preparations | 1 | 2021 | 276 | 0.67 | Why? |
| Intellectual Property | 1 | 2018 | 76 | 0.67 | Why? |
| Drug Discovery | 3 | 2021 | 3092 | 0.66 | Why? |
| Technology, Pharmaceutical | 1 | 2017 | 82 | 0.66 | Why? |
| Antiparkinson Agents | 1 | 2018 | 125 | 0.66 | Why? |
| Genes, Transgenic, Suicide | 1 | 2016 | 4 | 0.65 | Why? |
| Acute Generalized Exanthematous Pustulosis | 1 | 2018 | 96 | 0.65 | Why? |
| Orbital Diseases | 1 | 2021 | 339 | 0.65 | Why? |
| Abnormalities, Drug-Induced | 1 | 2017 | 72 | 0.64 | Why? |
| Blood-Brain Barrier | 2 | 2019 | 531 | 0.64 | Why? |
| Cosmetics | 1 | 2017 | 100 | 0.62 | Why? |
| Cell Culture Techniques | 1 | 2021 | 704 | 0.62 | Why? |
| Cannabinoids | 1 | 2018 | 134 | 0.62 | Why? |
| Nitriles | 1 | 2021 | 1053 | 0.62 | Why? |
| Post-Exposure Prophylaxis | 1 | 2020 | 472 | 0.61 | Why? |
| Epilepsy | 2 | 2018 | 1401 | 0.60 | Why? |
| Acetamides | 1 | 2017 | 141 | 0.60 | Why? |
| Bronchodilator Agents | 1 | 2021 | 444 | 0.60 | Why? |
| Disease Models, Animal | 6 | 2020 | 10998 | 0.59 | Why? |
| Gene Transfer Techniques | 1 | 2016 | 134 | 0.58 | Why? |
| Product Surveillance, Postmarketing | 1 | 2017 | 189 | 0.58 | Why? |
| Pharmaceutical Preparations | 2 | 2021 | 1897 | 0.56 | Why? |
| India | 11 | 2021 | 11875 | 0.56 | Why? |
| Plants, Medicinal | 1 | 2021 | 622 | 0.56 | Why? |
| Opportunistic Infections | 1 | 2021 | 602 | 0.56 | Why? |
| Steroids | 1 | 2020 | 904 | 0.56 | Why? |
| Drugs, Investigational | 1 | 2017 | 198 | 0.55 | Why? |
| Bacterial Toxins | 1 | 2016 | 185 | 0.54 | Why? |
| Nitric Oxide | 1 | 2021 | 769 | 0.53 | Why? |
| Pharmacovigilance | 1 | 2018 | 501 | 0.53 | Why? |
| Protein Interaction Domains and Motifs | 1 | 2020 | 2134 | 0.49 | Why? |
| Anti-Bacterial Agents | 3 | 2021 | 10083 | 0.49 | Why? |
| Cognition Disorders | 1 | 2018 | 574 | 0.49 | Why? |
| Mucormycosis | 1 | 2021 | 832 | 0.45 | Why? |
| Seizures | 2 | 2017 | 1163 | 0.44 | Why? |
| Drug Resistance, Bacterial | 1 | 2021 | 1414 | 0.44 | Why? |
| Printing, Three-Dimensional | 1 | 2017 | 624 | 0.44 | Why? |
| Ivermectin | 1 | 2021 | 973 | 0.44 | Why? |
| Genetic Therapy | 1 | 2016 | 409 | 0.44 | Why? |
| Drug Approval | 1 | 2020 | 1325 | 0.43 | Why? |
| Rats, Wistar | 3 | 2017 | 621 | 0.43 | Why? |
| Transportation | 1 | 2017 | 691 | 0.43 | Why? |
| Drug Design | 2 | 2020 | 2627 | 0.43 | Why? |
| Enzyme Inhibitors | 1 | 2021 | 1881 | 0.42 | Why? |
| Coronavirus Infections | 17 | 2021 | 253789 | 0.41 | Why? |
| Drug Industry | 1 | 2018 | 689 | 0.40 | Why? |
| BCG Vaccine | 1 | 2020 | 1137 | 0.40 | Why? |
| Renal Insufficiency | 1 | 2017 | 810 | 0.39 | Why? |
| Zoonoses | 2 | 2020 | 3034 | 0.39 | Why? |
| Animals | 19 | 2021 | 78931 | 0.39 | Why? |
| Pyrazines | 1 | 2020 | 1783 | 0.38 | Why? |
| Mesenchymal Stem Cell Transplantation | 1 | 2021 | 1322 | 0.38 | Why? |
| Amides | 1 | 2020 | 1864 | 0.38 | Why? |
| Autism Spectrum Disorder | 1 | 2017 | 587 | 0.38 | Why? |
| Genetic Vectors | 1 | 2016 | 1600 | 0.36 | Why? |
| Biomedical Research | 2 | 2021 | 5270 | 0.36 | Why? |
| Alzheimer Disease | 1 | 2018 | 1020 | 0.35 | Why? |
| Pneumonia, Viral | 14 | 2020 | 243684 | 0.35 | Why? |
| Clinical Trials as Topic | 4 | 2021 | 7330 | 0.34 | Why? |
| Research | 1 | 2020 | 2115 | 0.33 | Why? |
| Povidone-Iodine | 2 | 2020 | 213 | 0.33 | Why? |
| Severe Acute Respiratory Syndrome | 2 | 2021 | 12361 | 0.33 | Why? |
| Humans | 49 | 2021 | 930598 | 0.30 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.30 | Why? |
| Parkinson Disease | 1 | 2018 | 1414 | 0.30 | Why? |
| Peptides | 1 | 2018 | 2513 | 0.29 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.29 | Why? |
| Chloroquine | 1 | 2020 | 3152 | 0.29 | Why? |
| Bacteria | 1 | 2016 | 1897 | 0.28 | Why? |
| Drug Repositioning | 5 | 2021 | 5683 | 0.28 | Why? |
| Viral Proteins | 2 | 2020 | 7370 | 0.27 | Why? |
| Betacoronavirus | 11 | 2020 | 204454 | 0.27 | Why? |
| Immunologic Factors | 1 | 2020 | 4206 | 0.26 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.25 | Why? |
| Molecular Dynamics Simulation | 3 | 2021 | 4155 | 0.25 | Why? |
| Nervous System Diseases | 1 | 2021 | 4092 | 0.24 | Why? |
| SARS Virus | 3 | 2020 | 13021 | 0.24 | Why? |
| Oxidative Stress | 3 | 2018 | 2050 | 0.23 | Why? |
| Treatment Outcome | 8 | 2021 | 51732 | 0.23 | Why? |
| Pandemics | 16 | 2021 | 389249 | 0.23 | Why? |
| Immunotherapy | 1 | 2016 | 2421 | 0.23 | Why? |
| Universities | 1 | 2017 | 4374 | 0.23 | Why? |
| Hyperhomocysteinemia | 1 | 2021 | 24 | 0.22 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 2 | 2020 | 8843 | 0.22 | Why? |
| Swine | 2 | 2020 | 3352 | 0.22 | Why? |
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2021 | 37 | 0.22 | Why? |
| Liver Diseases | 1 | 2017 | 2698 | 0.22 | Why? |
| Coinfection | 1 | 2021 | 6820 | 0.22 | Why? |
| Nitric Oxide Synthase Type III | 1 | 2021 | 87 | 0.21 | Why? |
| Mutation | 1 | 2021 | 12376 | 0.21 | Why? |
| Molecular Targeted Therapy | 2 | 2020 | 1579 | 0.21 | Why? |
| Computer-Aided Design | 1 | 2021 | 94 | 0.21 | Why? |
| Naltrexone | 1 | 2020 | 56 | 0.21 | Why? |
| Antipsychotic Agents | 2 | 2019 | 887 | 0.20 | Why? |
| Sepsis | 1 | 2017 | 3517 | 0.20 | Why? |
| Legislation, Drug | 1 | 2020 | 101 | 0.20 | Why? |
| Brain | 1 | 2017 | 5133 | 0.20 | Why? |
| Group IV Phospholipases A2 | 1 | 2018 | 14 | 0.19 | Why? |
| Leptospermum | 1 | 2018 | 2 | 0.19 | Why? |
| Tinidazole | 1 | 2018 | 9 | 0.19 | Why? |
| Dexamethasone | 2 | 2020 | 2055 | 0.19 | Why? |
| Phospholipase A2 Inhibitors | 1 | 2018 | 26 | 0.19 | Why? |
| Arachidonic Acids | 1 | 2018 | 36 | 0.19 | Why? |
| Cytokines | 3 | 2018 | 15010 | 0.19 | Why? |
| Protein Phosphatase 2 | 1 | 2018 | 18 | 0.19 | Why? |
| Trichomonas Infections | 1 | 2018 | 24 | 0.19 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.19 | Why? |
| Poultry | 1 | 2020 | 437 | 0.19 | Why? |
| Camelids, New World | 1 | 2020 | 276 | 0.19 | Why? |
| Protein Kinase C | 1 | 2018 | 58 | 0.19 | Why? |
| Glycogen Synthase Kinase 3 beta | 1 | 2018 | 45 | 0.18 | Why? |
| Rodentia | 1 | 2020 | 235 | 0.18 | Why? |
| Streptococcus mutans | 1 | 2018 | 15 | 0.18 | Why? |
| Metronidazole | 1 | 2018 | 59 | 0.18 | Why? |
| Giardiasis | 1 | 2018 | 34 | 0.18 | Why? |
| Pentylenetetrazole | 1 | 2017 | 2 | 0.18 | Why? |
| Cyclooxygenase 2 Inhibitors | 1 | 2018 | 48 | 0.18 | Why? |
| Ibuprofen | 1 | 2020 | 156 | 0.18 | Why? |
| Tail | 1 | 2017 | 5 | 0.18 | Why? |
| Caspases | 1 | 2018 | 156 | 0.18 | Why? |
| ATP-Binding Cassette Transporters | 1 | 2018 | 48 | 0.18 | Why? |
| Tooth Abnormalities | 1 | 2017 | 7 | 0.18 | Why? |
| Antiparasitic Agents | 1 | 2021 | 267 | 0.18 | Why? |
| Aqueous Humor | 1 | 2018 | 82 | 0.18 | Why? |
| Databases, Pharmaceutical | 1 | 2020 | 345 | 0.18 | Why? |
| Electroshock | 1 | 2017 | 7 | 0.18 | Why? |
| Caspase 9 | 1 | 2017 | 38 | 0.17 | Why? |
| Carbon Tetrachloride | 1 | 2017 | 27 | 0.17 | Why? |
| Diclofenac | 1 | 2017 | 27 | 0.17 | Why? |
| tau Proteins | 1 | 2018 | 162 | 0.17 | Why? |
| Randomized Controlled Trials as Topic | 3 | 2021 | 10649 | 0.17 | Why? |
| Memory Disorders | 1 | 2019 | 190 | 0.17 | Why? |
| Critical Illness | 1 | 2021 | 17281 | 0.17 | Why? |
| Calcifediol | 1 | 2018 | 191 | 0.16 | Why? |
| Caspase 3 | 1 | 2017 | 218 | 0.16 | Why? |
| Paralysis | 1 | 2017 | 92 | 0.16 | Why? |
| Solubility | 1 | 2017 | 382 | 0.16 | Why? |
| Diffusion of Innovation | 1 | 2021 | 440 | 0.16 | Why? |
| Genitalia | 1 | 2017 | 98 | 0.16 | Why? |
| Tobacco | 1 | 2018 | 274 | 0.16 | Why? |
| Valproic Acid | 1 | 2017 | 114 | 0.16 | Why? |
| Host-Pathogen Interactions | 3 | 2021 | 11041 | 0.16 | Why? |
| Drug Therapy, Combination | 2 | 2020 | 7268 | 0.15 | Why? |
| Surface Properties | 1 | 2017 | 448 | 0.15 | Why? |
| Cerebral Infarction | 1 | 2019 | 245 | 0.15 | Why? |
| Disease Outbreaks | 2 | 2021 | 27595 | 0.15 | Why? |
| Gene Expression Regulation, Bacterial | 1 | 2016 | 143 | 0.15 | Why? |
| Capillary Permeability | 1 | 2017 | 277 | 0.15 | Why? |
| Catechin | 1 | 2019 | 244 | 0.15 | Why? |
| Molecular Epidemiology | 1 | 2021 | 1638 | 0.15 | Why? |
| TOR Serine-Threonine Kinases | 1 | 2018 | 385 | 0.15 | Why? |
| Inhibitory Concentration 50 | 1 | 2018 | 907 | 0.15 | Why? |
| Problem-Based Learning | 1 | 2020 | 363 | 0.14 | Why? |
| Chromatography, High Pressure Liquid | 1 | 2018 | 669 | 0.14 | Why? |
| Ferrets | 1 | 2020 | 1201 | 0.14 | Why? |
| Administration, Inhalation | 1 | 2021 | 1647 | 0.14 | Why? |
| Smoke | 1 | 2018 | 349 | 0.14 | Why? |
| Catalytic Domain | 1 | 2021 | 1757 | 0.14 | Why? |
| Patient Selection | 2 | 2020 | 4560 | 0.14 | Why? |
| Cannabis | 1 | 2018 | 284 | 0.13 | Why? |
| Cats | 1 | 2020 | 1890 | 0.13 | Why? |
| Anti-Infective Agents, Local | 1 | 2020 | 520 | 0.13 | Why? |
| Cell Death | 1 | 2016 | 536 | 0.13 | Why? |
| Rare Diseases | 1 | 2017 | 373 | 0.13 | Why? |
| Adverse Drug Reaction Reporting Systems | 1 | 2018 | 694 | 0.13 | Why? |
| Administration, Oral | 2 | 2018 | 2340 | 0.13 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.12 | Why? |
| Dogs | 1 | 2020 | 2529 | 0.12 | Why? |
| Pseudomonas aeruginosa | 1 | 2018 | 652 | 0.12 | Why? |
| Antimicrobial Stewardship | 1 | 2021 | 931 | 0.12 | Why? |
| Lipopolysaccharides | 1 | 2017 | 848 | 0.12 | Why? |
| Eye Infections, Viral | 1 | 2020 | 517 | 0.12 | Why? |
| Tandem Mass Spectrometry | 1 | 2018 | 1031 | 0.12 | Why? |
| RNA | 1 | 2020 | 1278 | 0.12 | Why? |
| Immunization, Secondary | 1 | 2020 | 1649 | 0.12 | Why? |
| Immunomodulation | 1 | 2021 | 1472 | 0.11 | Why? |
| Camelus | 1 | 2020 | 1425 | 0.11 | Why? |
| Hypertension, Pulmonary | 1 | 2021 | 970 | 0.11 | Why? |
| Interleukins | 1 | 2017 | 762 | 0.11 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 1 | 2018 | 711 | 0.11 | Why? |
| Spike Glycoprotein, Coronavirus | 2 | 2020 | 37182 | 0.11 | Why? |
| Antifungal Agents | 1 | 2021 | 1828 | 0.10 | Why? |
| Neoplasms | 2 | 2017 | 17251 | 0.10 | Why? |
| Alveolar Epithelial Cells | 1 | 2018 | 1445 | 0.10 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.10 | Why? |
| Drug Delivery Systems | 1 | 2020 | 1365 | 0.10 | Why? |
| Mass Vaccination | 1 | 2020 | 1101 | 0.10 | Why? |
| Area Under Curve | 1 | 2017 | 2564 | 0.10 | Why? |
| Escherichia coli | 1 | 2017 | 1547 | 0.10 | Why? |
| Cells, Cultured | 1 | 2021 | 5835 | 0.10 | Why? |
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 1014 | 0.10 | Why? |
| Rats | 1 | 2017 | 2764 | 0.10 | Why? |
| Genotype | 1 | 2021 | 4697 | 0.10 | Why? |
| Sex Characteristics | 1 | 2017 | 1120 | 0.09 | Why? |
| Psychotic Disorders | 1 | 2019 | 924 | 0.09 | Why? |
| Viral Vaccines | 2 | 2020 | 7560 | 0.09 | Why? |
| Adaptive Immunity | 1 | 2020 | 2585 | 0.09 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 1454 | 0.09 | Why? |
| Antimalarials | 1 | 2020 | 2505 | 0.09 | Why? |
| Nucleocapsid Proteins | 1 | 2020 | 3120 | 0.09 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.08 | Why? |
| Protein Binding | 2 | 2021 | 11430 | 0.08 | Why? |
| Point-of-Care Testing | 1 | 2020 | 2782 | 0.08 | Why? |
| Evidence-Based Medicine | 1 | 2020 | 3228 | 0.08 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2017 | 2483 | 0.08 | Why? |
| Telemedicine | 1 | 2018 | 25032 | 0.08 | Why? |
| Models, Molecular | 1 | 2020 | 7616 | 0.08 | Why? |
| Dietary Supplements | 1 | 2018 | 2251 | 0.08 | Why? |
| Clinical Decision-Making | 1 | 2020 | 3755 | 0.08 | Why? |
| Mice | 3 | 2020 | 21357 | 0.08 | Why? |
| Artificial Intelligence | 1 | 2021 | 3543 | 0.07 | Why? |
| Predictive Value of Tests | 1 | 2021 | 9537 | 0.07 | Why? |
| Chiroptera | 1 | 2020 | 3530 | 0.07 | Why? |
| Computer Simulation | 1 | 2020 | 4982 | 0.07 | Why? |
| Azithromycin | 1 | 2020 | 3943 | 0.07 | Why? |
| Developing Countries | 1 | 2020 | 4283 | 0.07 | Why? |
| Research Design | 1 | 2021 | 5830 | 0.07 | Why? |
| Disease Susceptibility | 1 | 2017 | 4002 | 0.07 | Why? |
| Weight Gain | 2 | 2019 | 552 | 0.07 | Why? |
| Pregnancy Outcome | 1 | 2017 | 3803 | 0.07 | Why? |
| Reproducibility of Results | 1 | 2020 | 11304 | 0.06 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.06 | Why? |
| Alanine | 1 | 2020 | 5687 | 0.06 | Why? |
| Kidney | 1 | 2017 | 3648 | 0.06 | Why? |
| Liver | 1 | 2017 | 4007 | 0.06 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 5277 | 0.06 | Why? |
| Models, Theoretical | 1 | 2021 | 6659 | 0.06 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.06 | Why? |
| Antineoplastic Agents | 1 | 2017 | 3550 | 0.06 | Why? |
| Povidone | 1 | 2020 | 21 | 0.05 | Why? |
| Administration, Ophthalmic | 1 | 2020 | 53 | 0.05 | Why? |
| Ghrelin | 1 | 2019 | 22 | 0.05 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.05 | Why? |
| Male | 7 | 2021 | 367725 | 0.05 | Why? |
| Receptors, Neurotransmitter | 1 | 2018 | 10 | 0.05 | Why? |
| Risperidone | 1 | 2019 | 55 | 0.05 | Why? |
| Brazil | 1 | 2017 | 12582 | 0.05 | Why? |
| Ophthalmic Solutions | 1 | 2020 | 136 | 0.05 | Why? |
| Sensitivity and Specificity | 1 | 2020 | 22971 | 0.05 | Why? |
| Viral Load | 1 | 2020 | 15850 | 0.05 | Why? |
| Emulsions | 1 | 2019 | 80 | 0.05 | Why? |
| Carbohydrate Metabolism | 1 | 2018 | 44 | 0.05 | Why? |
| Prevalence | 1 | 2021 | 25773 | 0.05 | Why? |
| Neurotransmitter Agents | 1 | 2018 | 57 | 0.05 | Why? |
| Virus Replication | 1 | 2020 | 14331 | 0.05 | Why? |
| Drug Liberation | 1 | 2019 | 141 | 0.05 | Why? |
| Behavior, Animal | 1 | 2019 | 136 | 0.04 | Why? |
| Neuropeptides | 1 | 2018 | 91 | 0.04 | Why? |
| Leptin | 1 | 2019 | 141 | 0.04 | Why? |
| Adult | 3 | 2021 | 244371 | 0.04 | Why? |
| Reward | 1 | 2018 | 146 | 0.04 | Why? |
| Biological Availability | 1 | 2019 | 388 | 0.04 | Why? |
| Prognosis | 1 | 2021 | 32490 | 0.04 | Why? |
| Retrospective Studies | 2 | 2021 | 105322 | 0.04 | Why? |
| Global Health | 1 | 2021 | 13911 | 0.04 | Why? |
| Risk Assessment | 1 | 2021 | 25439 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.04 | Why? |
| Female | 6 | 2021 | 380317 | 0.04 | Why? |
| Drug Compounding | 1 | 2019 | 386 | 0.04 | Why? |
| Comorbidity | 1 | 2021 | 34796 | 0.04 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.04 | Why? |
| Rabbits | 1 | 2018 | 1171 | 0.04 | Why? |
| Time Factors | 1 | 2018 | 31397 | 0.03 | Why? |
| Pregnancy | 1 | 2017 | 23879 | 0.03 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 8811 | 0.03 | Why? |
| Energy Metabolism | 1 | 2018 | 451 | 0.03 | Why? |
| Lipid Metabolism | 1 | 2018 | 572 | 0.03 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.03 | Why? |
| Body Weight | 1 | 2019 | 1074 | 0.03 | Why? |
| Risk Factors | 1 | 2021 | 71621 | 0.03 | Why? |
| Lipids | 1 | 2019 | 1079 | 0.03 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2021 | 1138 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.03 | Why? |
| Patients | 1 | 2017 | 1167 | 0.02 | Why? |
| Schizophrenia | 1 | 2019 | 1018 | 0.02 | Why? |
| Mice, Inbred BALB C | 1 | 2019 | 5814 | 0.02 | Why? |
| Hyperglycemia | 1 | 2019 | 1363 | 0.02 | Why? |
| Adolescent | 1 | 2018 | 86841 | 0.02 | Why? |
| Nanoparticles | 1 | 2019 | 2040 | 0.02 | Why? |
| Gastrointestinal Microbiome | 1 | 2018 | 1961 | 0.02 | Why? |
| Molecular Docking Simulation | 1 | 2020 | 6902 | 0.02 | Why? |
| RNA, Messenger | 1 | 2018 | 5131 | 0.02 | Why? |
| Cell Line | 1 | 2018 | 12040 | 0.02 | Why? |
| Middle Aged | 1 | 2020 | 270681 | 0.01 | Why? |
| Nurses | 1 | 2017 | 2285 | 0.01 | Why? |
| Tertiary Care Centers | 1 | 2017 | 8248 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2021 | 53120 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.01 | Why? |